Phase 1b/2a Single-center, Open-label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of MN-166 (Ibudilast) and Temozolomide Combination Treatment in Patients With Newly Diagnosed or Recurrent Glioblastoma
Latest Information Update: 22 Aug 2024
At a glance
- Drugs Ibudilast (Primary) ; Temozolomide (Primary)
- Indications Astrocytoma; Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors MediciNova
- 20 Aug 2024 Planned End Date changed from 30 Jun 2024 to 30 Dec 2024.
- 04 Jun 2024 Primary endpoint (Evaluate efficacy of ibudilast and TMZ combination treatment) has been met, according to results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2024 Results assessing presented at the 60th Annual Meeting of the American Society of Clinical Oncology.